HMG here means human menopausal gonadotropin (menotropin), a urine-derived preparation of the pituitary glycoprotein hormones follicle-stimulating hormone (FSH) and luteinising hormone (LH), with human chorionic gonadotropin (hCG) contributing much of the LH-type activity. It is a mixture of glycoforms, not a single defined molecule. In the laboratory it is studied as a source of gonadotropin activity for receptor signalling assays, in-vitro follicle and gonadal cell culture, and glycoprotein analytical work. It should not be confused with HMG-CoA or with high-mobility group proteins, which share the abbreviation.
What is HMG?
Human menopausal gonadotropin is a purified extract of the urine of postmenopausal women. After menopause, the pituitary secretes large amounts of FSH and LH because ovarian feedback has declined, and these hormones are excreted in urine. Extraction and purification yields a preparation whose biological activity is standardised in international units (IU) of FSH and LH activity, not by mass. Modern preparations are highly purified, but they remain heterogeneous.
The active components are heterodimeric glycoproteins. FSH and LH share a common α-subunit of 92 amino acids, which is also found in thyroid-stimulating hormone and hCG, and each has a hormone-specific β-subunit that determines receptor selectivity: about 111 residues for FSH and about 121 for LH. Each subunit carries N-linked carbohydrate chains, and the dimers are stabilised by multiple disulfide bonds in a cystine-knot fold. Total molecular masses are about 30 kDa, with the carbohydrate making up a large share. Because glycosylation varies, each hormone exists as a family of isoforms with different charge and sialic acid content, which is why preparations are described as isoform mixtures. In urinary menotropin, hCG-derived material adds to the LH-type activity, and other urinary proteins can remain as impurities.
The history is well documented. The 1930s saw the discovery and early clinical use of gonadotropin extracts from animal pituitaries, pregnant mare serum and human sources, and Bruno Lunenfeld’s 2004 review traces how these evolved. Piero Donini developed methods to extract gonadotropins from the urine of postmenopausal women in 1949, and Donini and colleagues later published a purification of the gonadotropin by gel filtration on Sephadex in 1964. Collaboration between Lunenfeld and Donini produced a preparation that became the first human gonadotropin drug in the early 1960s. That pharmaceutical use is a licensed medicinal context, quite separate from research-grade material, and nothing in this article concerns it.
Mechanism of action
FSH and LH act on two related receptors, the FSH receptor (FSHR) and the LH/choriogonadotropin receptor (LHCGR). Both are class A G protein-coupled receptors (GPCRs) with a large N-terminal leucine-rich ectodomain that binds the glycoprotein hormone with high affinity and a seven-transmembrane domain that transmits the signal. The β-subunit confers specificity: FSH binds FSHR, while LH and hCG bind LHCGR, and hCG, with a longer β-subunit, is a more potent and longer-lived agonist at LHCGR than LH.
The canonical signalling route runs through the stimulatory G protein Gs. Receptor activation stimulates adenylyl cyclase, raising cyclic AMP, which activates protein kinase A and the transcription factor CREB. Both receptors can also signal through other routes, including Gq, β-arrestin recruitment and the ERK and PI3K/AKT pathways, and the balance depends on cell type, receptor density and the glycoform present.
In cellular systems, the two hormones act on distinct cell types. FSHR is expressed on granulosa cells in the ovary and Sertoli cells in the testis, while LHCGR is expressed on theca cells and luteinised granulosa cells and on Leydig cells. This distribution underlies the two-cell model of steroidogenesis, in which LH-stimulated theca or Leydig cells produce androgens and FSH-stimulated granulosa cells convert them using aromatase.
Two experimental implications follow. First, because HMG contains FSH, LH and hCG activity together, responses in cells expressing both receptors cannot be attributed to one hormone without selective controls, such as receptor-specific cell lines, neutralising antibodies or purified single-hormone references. Second, glycoform composition affects both receptor binding and circulating persistence, so batch-to-batch differences in isoform profile can change dose-response curves.
What the research shows
Four sets of published work frame the field.
The first is the historical account of how gonadotropin preparations were developed. Lunenfeld’s 2004 review in Human Reproduction Update describes the progression from animal pituitary and pregnant mare serum extracts, through human pituitary, placental and urinary preparations, to recombinant hormones produced in Chinese hamster ovary cells. It places human menopausal gonadotropin within this sequence and documents the milestones in the purification of the hormones. The review is indexed on PubMed.
The second concerns purification. Donini, Puzzuoli and D’Alessio reported in Acta Endocrinologica in 1964 the purification of gonadotropin from menopausal urine by gel filtration on Sephadex, which was an early application of size-based chromatography to remove urinary contaminants and concentrate activity. The work illustrates why the product is a purified mixture, and not a single molecule.
The third is a compositional analysis. Van de Weijer and colleagues reported in Reproductive BioMedicine Online in 2003 a compositional analysis of a human menopausal gonadotropin preparation extracted from urine, and identified some of its major impurities. The study showed that even a purified preparation contains proteins other than the intended hormones, which is why impurity profiling matters.
The fourth is a batch-consistency study. Wolfenson and colleagues, in Reproductive BioMedicine Online in 2005, used oligosaccharide isoform profiling, immunoassay, size-exclusion chromatography and an in-vitro follicle bioassay to compare urinary-derived and recombinant gonadotropin preparations. They reported that the urinary-derived products showed a high degree of batch-to-batch consistency, similar to the recombinant FSH tested, and that the total FSH bioactivity delivered from single-dose preparations after reconstitution differed depending on whether the product was filled by mass or by bioassay. A record of the paper is available through the University of Buenos Aires digital library. Its results concern specific licensed products, and they should not be extended to unlicensed or research-grade material.
Research applications
Receptor pharmacology is the main use. Cell lines expressing human FSHR or LHCGR, such as transfected HEK293 or CHO cells, are stimulated with gonadotropin preparations, and the response is measured by cyclic AMP accumulation, CRE-reporter activity or ERK phosphorylation. Because the preparation contains several active components, such assays are usually run alongside purified single-hormone standards.
Gonadal cell culture is a second area. Primary granulosa cells, granulosa-derived lines such as KGN, Sertoli cells and Leydig lines such as mouse MA-10 cells respond to gonadotropins with steroid production and changes in gene expression, and they are used to study steroidogenic enzymes and receptor signalling. In-vitro follicle culture and bioassays are a third area, in which isolated follicles from animal tissue are cultured with the preparation, as in the model used for consistency testing, and growth and maturation are monitored. Animal studies of gonadal physiology, carried out by licensed investigators under the Animals (Scientific Procedures) Act 1986, form a fourth area.
Analytical glycobiology is a fifth. Preparations are a standard test case for glycoprotein characterisation: isoelectric focusing, capillary electrophoresis, HILIC analysis of released glycans, size-exclusion chromatography and mass spectrometry are used to profile isoforms and quantify impurities. Immunoassay development is a sixth, where the material serves as a calibrant or cross-reactivity test sample for FSH, LH and hCG assays.
Purity, storage and handling
Quality control of a glycoprotein mixture differs from that of a synthetic peptide. Purity by a single HPLC peak is not meaningful, so a good certificate relies on several orthogonal measurements: size-exclusion chromatography for aggregates and fragments, SDS-PAGE or capillary electrophoresis for the protein profile, reversed-phase HPLC for subunit composition, glycan or isoform profiling, and immunoassays that quantify FSH, LH and hCG separately. Potency should be expressed as biological activity from a validated bioassay or a reference-standard-calibrated method, not from protein mass alone. Endotoxin testing is advisable for cell-based work, and documentation of the source material and any viral-safety steps is relevant for a urinary product.
Because degradation accelerates once reconstituted, batch-level verification matters more here than with more stable compounds. UK laboratories sourcing HMG should expect a batch-specific certificate of analysis and lyophilised storage at -20°C, and researchers asking How to buy best peptides can use those documentation requirements as a first filter when comparing vendors.
A batch-specific certificate matters because the mixture varies in composition. The proportions of FSH, LH and hCG activity, the isoform profile and the level of non-hormone proteins can all differ between lots, and the Wolfenson and Van de Weijer studies illustrate both consistency testing and impurity analysis. The certificate should show the batch number, the method for each activity and purity result, the units, the excipients present, the test date and the storage conditions.
Lyophilised material is generally stored sealed, desiccated and protected from light, with -20°C as a conservative choice for research stock, and the supplier’s own stability data should take priority. Reconstituted glycoproteins are more fragile than lyophilised powder. They should be dissolved by gentle swirling, since vigorous vortexing can cause aggregation and foaming, and used promptly or divided into single-use aliquots to avoid repeated freeze-thaw cycles. Low-binding tubes, or a carrier protein such as 0.1% bovine serum albumin in the diluent, help to prevent loss of dilute protein by adsorption. Deamidation, oxidation and aggregation can all reduce activity over time, and exact stability windows depend on buffer, pH, concentration and temperature, so they should be confirmed in-house for critical assays.
Light sensitivity is moderate, since the protein contains tryptophan and tyrosine, so amber vials or dark storage are advisable. Standard COSHH assessment applies, and because the material is of human origin, laboratories should follow their institutional biosafety rules for handling and disposal.
Frequently asked questions
What is HMG in research?
In this context HMG is human menopausal gonadotropin, or menotropin: a urine-derived preparation of the pituitary glycoprotein hormones FSH and LH, with hCG contributing much of the LH-type activity. It is a mixture of glycoforms, not a single defined molecule, and it is distinct from HMG-CoA or high-mobility group proteins.
Is HMG a peptide?
Not in the strict sense. FSH and LH are heterodimeric glycoproteins of roughly 30 kDa, built from a shared 92-residue α-subunit and a hormone-specific β-subunit, with attached carbohydrate chains. They are far larger than typical synthetic peptides and must be analysed as glycoproteins, using size-exclusion chromatography, glycan profiling and bioassay.
How is the potency of HMG measured?
Potency is expressed as biological activity in international units, not milligrams, because the preparation is a heterogeneous mixture. FSH and LH activity are assessed by validated bioassays and immunoassays, and in-vitro follicle bioassays have also been used to compare batch consistency. A certificate should state activity, not only protein content.
How should lyophilised HMG be stored?
Storage depends on the formulation and the supplier’s stability data, but lyophilised glycoprotein preparations are generally kept sealed, desiccated and protected from light, at -20°C for research stock. Reconstituted material should be handled gently without vortexing, used promptly or aliquoted, and not repeatedly freeze-thawed.
HMG is supplied for in-vitro laboratory research only. It is not for human or veterinary use, and it must not be administered to people or animals.